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70). Acute and maintenance phase costs were estimated
by assigning prices (in year 2000 dollars) from a standard
list to units of applicable medical services. Using a
trimmed-means (25% on each tail of the cost distribu-
tion) comparison to overcome the skewness in the distri-
bution of cost data, the medication treatment groups were
compared.
RESULTS: Overall per-patient costs were not signiﬁcantly
different between the olanzapine-treated patients (15.9 ±
4.5mg/day) and the divalproex-treated patients (1596.4
± 492.7mg/day). However, olanzapine treatment was
associated with signiﬁcantly higher medication costs (p <
.001), but signiﬁcantly lower outpatient (p < .001) and
overall inpatient (p < .05) costs over the course of treat-
ment. Outpatient costs were higher in divalproex-treated
patients due to higher emergency room and other outpa-
tient visits.
CONCLUSIONS: These ﬁndings suggest that differences
in medication acquisition cost are offset by lower costs
for other clinical services during olanzapine treatment.
Further research is needed to determine the extent to
which the present ﬁndings can be generalized to practice
settings outside of the clinical trial context.
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OBJECTIVE: To proﬁle treatment-resistant depression
(TRD) patients healthcare costs and medical care patterns
as their illness progresses.
METHODS: The MEDSTAT MarketScan® Database 
for 1995–2000 was used. Patients with a depression 
diagnosis, suicide attempt, or those treated with electro-
convulsive therapy were considered. TRD patients were
those who either switched or augmented their initial 
four-week (minimum) antidepressant prescription with at
least one more antidepressant prescribed for at least four
weeks. Demographic, treatment, and cost proﬁles were
constructed for periods covered by each subsequent 
antidepressant medication switch or augmentation. Total
medical expenditures per day (year-2000 dollars) were
calculated and compared for periods between the index
date (entry into study) and each subsequent medication
switch or augmentation. Negative binomial count regres-
sion models were used to assess the impact of factors on
number of medication switches or augmentations occur-
ring during the study period.
RESULTS: The sample included 7,737 TRD patients;
72% female, 60% employees and 39% in managed care
plans. The mean number of medication switches or 
augmentations following the index prescription was 2.4.
Average total healthcare expenditures increased 102%
from $563 per month at the initial antidepressant switch
date to $1140 per month after six additional medication
switches or augmentations. The number of medication
switches or augmentations was signiﬁcantly inﬂuenced 
by the following factors: existence of comorbid mental
health problems, type of antidepressant prescribed at the
index date, type of depression diagnosis, treatment under
a managed care plan, single or family insurance coverage,
and length of time patients were followed.
CONCLUSIONS: Most treatment-resistant patients had
multiple medication switches or augmentations. Average
monthly expenditures more than doubled as the TRD
illness progressed through six additional medication
switches or augmentations. A better understanding of
factors associated with the number of medication
switches may lead to promising interventions improving
care for patients with treatment-resistant depression.
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OBJECTIVES: To estimate the long-term health and 
economic impact of treating patients with Alzheimer
disease with galantamine (Reminyl) in different countries.
METHODS: A pharmacoeconomic model, The 
Assessment of Health Economics of Alzheimer’s Disease
(AHEAD), was used to predict the time until Alzheimer’s
disease patients require full-time care and the associated
costs. Full-time care was the consistent requirement for a
signiﬁcant amount of care giving and supervision each
day. Efﬁcacy data were obtained from three clinical trials
comparing galantamine with placebo. For each country,
local data were obtained on service use, balance of care
between community and institutions, and relevant unit
costs. Analyses were completed for The Netherlands,
Sweden, Finland, Germany, UK, Canada and New
Zealand. Forecasts were made for up to ten years. Costs
are reported in 2001 currencies and determined from a
perspective somewhat broader than that of a compre-
hensive payer, including the cost to a national health
service as well as other relevant stakeholders such as
providers of social care services. Both health beneﬁts and
costs were discounted at 3%. Sensitivity analyses were
carried out on key input parameters and combinations of
these parameters.
RESULTS: In each country, full-time care was estimated
to account for at least two-thirds of the cost of caring 
for patients over ten years, and more than 60% of this
cost was from providing institutional care. Galantamine
is predicted to reduce the duration of full-time care by
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almost 12%. Approximately ﬁve patients need to be
placed on treatment to avoid one year of full-time care,
resulting in incremental savings in the majority of 
countries.
CONCLUSIONS: Delaying the time to full-time care is
expected to produce savings in the majority of health care
systems. Galantamine was considered to be an economi-
cally dominant strategy compared to no treatment in
most health care systems.
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“Revolving door” schizophrenia, characterized by fre-
quent hospitalizations, is very costly to the health care
system. Standard treatment is depot injection of typical
antipsychotics. Atypical antipsychotics in depot form are
expected to be more efﬁcacious that typical depots yet
will cost much more.
OBJECTIVES: We estimated the total healthcare costs,
from a third party payer perspective, of treating 
revolving door schizophrenia with depot formulations of
risperidone and olanzapine as compared to the status
quo, haloperidol decanoate.
METHODS: Because depot forms of risperidone and
olanzapine are in development, a modeling approach 
was used. The Markov model depicted events (medica-
tion adherence and relapse, deﬁned as hospitalization and
switch to clozapine) leading to three Markov states: in
community on depot, hospitalized, and in community on
clozapine. Clinical probabilities were derived from ran-
domized, controlled trials of comparable oral drugs. Unit
costs were obtained from an administrative database and
provincial fee schedule and formulary. Product costs for
the atypical depots were based on their respective oral
costs. Monte Carlo simulation of 10,000 patients was
done with a cycle length of one month and time horizon
of 5 years. Probabilistic sensitivity analyses were done 
on all data estimates using Monte Carlo simulation.
Threshold analyses were also done on the drug costs.
RESULTS: Total 5-year base case costs (SD) for haloperi-
dol, risperidone and olanzapine alternatives were (Can.)
$17,865 (10,867), $15,146 (9797) and $22,362 (6509)
respectively. Mean hospitalizations per patient were
lowest for olanzapine (0.68) and highest for haloperidol
(1.07). Total costs were sensitive only to the risperidone
and olanzapine product costs with thresholds of $160
and $177 per month, respectively.
CONCLUSION: Compared with haloperidol decanoate,
total healthcare costs for treating “revolving door” schiz-
ophrenia were greater for olanzapine depot and less for
risperidone depot. For olanzapine hospitalization savings
were insufﬁcient to offset its much higher product cost.
The relative impact of atypical depots on total healthcare
costs will depend strongly on their price.
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The new atypical antipsychotics, although more expen-
sive than traditional agents, may reduce the ﬁnancial
burden posed by schizophrenic illness.
OBJECTIVE: The objective of this study was to compare
risperidone versus olanzapine on their impact on the
mental health care costs of schizophrenia in a “real-
world” setting.
METHODS: This was a retrospective, comparative study
based on claims data obtained from two large health care
plans during 1996 and 1997. The primary variable ana-
lyzed was net patient mental health care cost per member
per month (PMPM), deﬁned as total mental health care
cost excluding antipsychotic drug cost during treatment
episodes with risperidone or olanzapine. The individual
components of net mental health care costs were also 
analyzed. Between-group comparisons (for patients who
received one or the other of the antipsychotics) were per-
formed, controlling for differences in patient characteris-
tics. Data was obtained from medical and prescription
drug claims of individuals with schizophrenic disorders.
Regression models combining risperidone and olanzapine
treatment episodes were estimated to determine their
effects on mental health resource use.
RESULTS: A total of 129 risperidone (128 individuals)
and 273 olanzapine (271 individuals) treatment episodes
for schizophrenic disorders fell within the study period.
Most components of mental health care costs were lower
with risperidone than with olanzapine. Depending on the
method of estimation, between-group regression models
showed that risperidone reduced net mental health care
cost PMPM by 36% p < 0.01) or 53% (p < 0.01) and
total mental health care cost PMPM (inclusive of antipsy-
chotic drug cost) by 32% (p < 0.01) or 44% (p < 0.01)
compared with olanzapine. The major difference between
risperidone and olanzapine users was in inpatient costs,
which were 58% or 68% ($168 or $266) lower PMPM
with risperidone, depending on the method of estimation.
CONCLUSION: Relative to olanzapine, risperidone is
associated with reduced mental health costs for schizo-
phrenia patients in managed care populations.
